Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market

EATONTOWN, N.J., April 30 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has signed an exclusive distribution agreement with BioHorizons, Inc., effective as of April 1, 2008, under which BioHorizons will market Osteotech's bone regeneration products to the dental market in 29 countries in Europe, the Middle East, Latin America and Asia. Osteotech and BioHorizons previously entered into an agreement for BioHorizons to distribute Osteotech's products to the United States dental market in 2000.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "Our domestic relationship with BioHorizons has been very successful and we are pleased to be able to expand this relationship overseas. We believe our bone regeneration products are the perfect solution for the new bone grafting procedures being developed to replace missing or extracted teeth with dental implants or as support for dentures, crowns and bridges."

BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including surgical planning software, regenerative products, dental implants, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 30, 2008 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.